OPEN ACCESS Freely available online

Journal of Cell Science & Therapy

ISSN: 2157-7013

Short Communication

Advances in Pluripotent Stem Cell Technology: Implications for Therapy

Kim Hong*

Department of Rehabilitation, Dongguk University, Seoul, South Korea

DESCRIPTION

Pluripotent Stem Cells (PSCs) have revolutionized the field of regenerative medicine, offering unprecedented opportunities for therapeutic development and disease modeming. Derived from sources such as Embryonic Stem Cells (ESCs) and Induced Pluripotent Stem Cells (iPSCs), these cells possess the remarkable ability to differentiate into virtually any cell type in the human body. This inherent plasticity makes them invaluable for studying disease mechanisms, screening potential drugs, and ultimately, developing cell-based therapies [1-3].

Pluripotent stem cell technology

One of the most significant advancements in PSC technology lies in the refinement of differentiation protocols. Researchers have developed sophisticated methods to coax PSCs into specific cell types relevant to various diseases, such as neurons for neurological disorders, cardio myocytes for heart diseases, and pancreatic beta cells for diabetes [4]. These differentiated cells not only mimic the characteristics of their native counterparts but also offer a platform for studying disease progression *in vitro*. This capability is important for understanding disease mechanisms at a cellular level and for screening new therapeutic compounds with higher precision and efficiency [5].

The advent of genome editing technologies, particularly CRISPR/Cas9, has enhanced the utility of PSCs in therapy. Scientists can now precisely edit the genome of PSCs to correct disease-causing mutations or introduce specific genetic modifications that enhance their therapeutic potential. This approach holds potential for treating genetic disorders where a single mutation is responsible for disease manifestation, such as cystic fibrosis or sickle cell disease. By correcting these mutations in PSCs and differentiating them into functional cell types, researchers can potentially generate patient-specific cells for transplantation, offering a personalized approach to treatment [6-8].

Pluripotent stem cell derived cells

PSC-derived cells present a viable approach to replacing damaged or malfunctioning tissues in the context of transplantation therapy. For example, PSC-derived retinal cells are being investigated as a potential treatment for retinal degenerative illnesses such as retinitis pigmentosa and Age-Related Macular Degeneration (AMD). These cells have the ability to fuse with the retina, improve vision, and possibly even stop the progression of illness. Similar to this, cardio myocytes produced from PSCs have the ability to restore damaged heart tissue following myocardial infarction, thereby addressing a significant global source of morbidity and mortality [9].

Moreover, the scalability of PSCs in culture makes them a practical source for generating large quantities of cells needed for therapy. This scalability is essential for overcoming the limitations of primary cell sources and adult stem cells, which have limited proliferation capacity or restricted differentiation potential. PSCs can be expanded indefinitely in culture while maintaining their pluripotency or differentiated state, ensuring a sustainable and consistent cell supply for clinical applications [10].

Challenges

Despite these advancements, several challenges remain before PSC-based therapies can be widely implemented in clinical settings. Safety concerns, such as tumorigenicity and immunogenicity, must be rigorously addressed to ensure the long-term safety and efficacy of PSC derived products. Strategies to enhance cell survival, engraftment, and functional integration into host tissues are also critical for maximizing therapeutic outcomes. Additionally, regulatory frameworks and ethical considerations surrounding the use of PSCs need to be carefully navigated to ensure responsible and equitable deployment of these technologies [11].

CONCLUSION

Advances in PSC technology hold immense potential for revolutionizing therapy across a wide spectrum of diseases. From

Correspondence to: Kim Hong, Department of Rehabilitation, Dongguk University, Seoul, South Korea, E-mail: honglee459@126.kr

Received: 01-Jul-2024, Manuscript No. JCEST-24-33047; **Editor assigned:** 03-Jul-2024, PreQC No. JCEST-24-33047 (PQ); **Reviewed:** 17-Jul-2024, QC No. JCEST-24-33047; **Revised:** 24-Jul-2024, Manuscript No. JCEST-24-33047 (R); **Published:** 02-Aug-2024, DOI: 10.35248/2157-7013.24.15.470

Citation: Hong K (2024) Advances in Pluripotent Stem Cell Technology: Implications for Therapy. J Cell Sci Therapy. 15:470.

disease modelling and drug discovery to cell replacement therapies and personalized medicine, PSCs provide opportunities to address previously untreatable conditions. With continued research efforts aimed at overcoming existing challenges and translating laboratory findings into clinical applications.

REFERENCES

1. Chetty S, Pagliuca FW, Honore C, Kweudjeu A, Rezania A, Melton DA. A simple tool to improve pluripotent stem cell differentiation. Nat Methods. 2013;10(6):553-556.
2. Kane NM, Xiao Q, Baker AH, Luo Z, Xu Q, Emanueli C. Pluripotent stem cell differentiation into vascular cells: a novel technology with promises for vascular re (generation). Pharmacol Ther. 2011;129(1):29-49.
3. Lim WF, Inoue-Yokoo T, Tan KS, Lai MI, Sugiyama D. Hematopoietic cell differentiation from embryonic and induced pluripotent stem cells. Stem cell res ther. 2013;4:1-11.
4. Dado D, Sagi M, Levenberg S, Zemel A. Mechanical control of stem cell differentiation. Regen Med. 2012;7(1):101-116.
5. Wang Y, Yates F, Naveiras O, Ernst P, Daley GQ. Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci. 2005;102(52):19081-19086.
6. Lund RD, Wang S, Klimanskaya I, Holmes T, Ramos-Kelsey R, Lu B, et al.Human embryonic stem cell–derived cells rescue visual function in dystrophic RCS rats. Cloning and stem cells. 2006;8(3): 189-99.
7. Yang L, Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453(7):524-528.
8. Ding DC, Shyu WC, Lin SZ. Mesenchymal stem cells. Cell Transplant. 2011;20(1):5-14.
9. Solter D. From teratocarcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat Rev Genet. 2006;7(4): 319-327.
10. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Hematopoietic stem cell transplantation: a global perspective. Jama. 2010;303(16):1617-1624.
11. Singh AK, McGuirk JP. Allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res. 2016;76(22): 6445-6451.